北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第三临床医学院  > 血液内科  > 期刊论文
学科主题: 临床医学
题名:
Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia
作者: Fu, Lin1,2; Shi, Jinlong3; Hu, Kai1,2; Wang, Jijun1,2; Wang, Weidong3; Ke, Xiaoyan1,2
关键词: MAPKBP1 ; prognostic biomarker ; CN-AML
刊名: ONCOTARGET
发表日期: 2015-04-10
卷: 6, 期:10, 页:8144-8154
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Cell Biology
研究领域[WOS]: Oncology ; Cell Biology
关键词[WOS]: NF-KAPPA-B ; MICRORNA-EXPRESSION SIGNATURES ; OLDER PATIENTS ; DISTINCT GENE ; MUTATIONS ; CANCER ; PROFILES ; SUBTYPES ; IMPACT ; CELLS
英文摘要:

Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is a key transcription factor in the NF-kappa B signalling pathway. In this study, associations between MAPKBP1 expression and molecular and clinical characteristics were evaluated by several microarray datasets. We found that MAPKBP1 was over-expressed in cytogenetically normal AML (CN-AML) patients compared to normal bone marrow. High MAPKBP1 expression (MAPKBP1(high)) was associated with significantly shorter event-free survival (EFS; P = 0.0004) and overall survival (OS; P = 0.0006) than low MAPKBP1 expression (MAPKBP1(low)) in a cohort of 157 CN-AML patients. In multivariable analyses, MAPKBP1(high) remained associated with shorter EFS (P = 0.003) and OS (P = 0.01). Validation in an independent cohort of 162 CN-AML patients further confirmed the prognostic value of MAPKBP1 (OS, P = 0.00172). Gene-expression profiling revealed that some important oncogenes, including MYCN, MYB, CDK6 and CCND2, etc, were up-regulated, while cell signalling pathways leading to apoptosis, antigen processing, and natural killer cell-mediated cytotoxicity were down-regulated in MAPKBP1(high) patients with CN-AML. MicroRNA expression profiling revealed that some oncogenic microRNAs including miR-155 and miR-126 were up-regulated, whilst anti-oncogenic microRNAs including miR-148a and miR-193a were down-regulated in MAPKBP1(high) patients with CN-AML, which may underlie the pathological processes in this malignancy. Taken together, these findings suggest MAPKBP1(high) is a novel, unfavourably prognostic biomarker for CN-AML risk-stratification.

语种: 英语
所属项目编号: 81172245 ; 61372047 ; 2013BAI03B04
项目资助者: National Natural Science Foundation of China ; National High-tech R&amp ; D Program of China
WOS记录号: WOS:000354885300057
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51313
Appears in Collections:北京大学第三临床医学院_血液内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 3, Dept Hematol, Beijing 100871, Peoples R China
2.Peking Univ, Hosp 3, Lymphoma Res Ctr, Beijing 100871, Peoples R China
3.Chinese Peoples Liberat Army Gen Hosp, Med Engn Support Ctr, Beijing 100853, Peoples R China

Recommended Citation:
Fu, Lin,Shi, Jinlong,Hu, Kai,et al. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia[J]. ONCOTARGET,2015,6(10):8144-8154.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Fu, Lin]'s Articles
[Shi, Jinlong]'s Articles
[Hu, Kai]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Fu, Lin]‘s Articles
[Shi, Jinlong]‘s Articles
[Hu, Kai]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace